We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit

Urbaniak-Kujda D, Biernat MM, Skalec T, et al. Haemophilia. 2021 Jul;27(4):e567-e570

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation

Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. J Thromb Haemost. 2020 Sep;18(9):2205-2208

Usefulness of Chromogenic Assays for Potency Assignment and Recovery of Plasma-Derived FVIII and FIX Concentrates or Their Recombinant Long Acting Therapeutic Equivalents With Potential Application in Treated Pediatric Hemophiliac Patients.

Amiral J and Seghatchian J. Transfus Apher Sci 2018;57:363–369.    

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Kitazawa T, Esaki K, Tachibana T, et al. Thromb Haemost. 2017;117(7):1348-1357.

Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons With Hemophilia A.

Retout S, Schmitt C, Petry C, et al. Clin Pharmacokinet 2020;doi: 10.1007/s40262-020-00904-z (epub ahead of print).

Spotlight on Emicizumab in the Management of Hemophilia A: Patient Selection and Special Considerations

Yada K and Nogami K. J Blood Med 2019;10:171–181.

Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab

Teo HKW, Wong WH, Lam JCM. Haemophilia. 2021 May;27(3):e415-e418.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Kitazawa T, Shima M. Int J Hematol. 2020;111:20–30.

Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data

Misgav M, Brutman-Barazani T, Budnik I, et al. Haemophilia. 2021 Mar;27(2):253-260.

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Nakajima Y, Nogami K, Yada K, et al. Thromb Haemost 2020;120:968–976.